Effect of Transfer Energy Capacitive and Resistive Therapy on Pain and Range of Motion After Flexor Tendon Repair

The purpose of this study is to evaluate the impact of Transfer Energy Capacitive and Resistive therapy (TECAR) on pain and range of motion (ROM) after hand flexor tendon repair.

Study Overview

• Status: Not yet recruiting
• Conditions: Flexor Tendon Rupture
• Intervention / Treatment: Device: Transfer Energy Capacitive and Resistive (TECAR) therapy; Other: Early mobilization protocol

Detailed Description

Lacking satisfactory healing of intrasynovial tendons, such as the flexor tendons of the hand, is particularly challenging due to the formation of fibrous adhesions between the tendon, sheath and surrounding tissues which can further limit mobility.

Transfer Energy Capacitive and Resistive therapy (TECAR) enhances the body's natural ability to repair tissues and reduce pain by improving blood flow and promoting additional benefits, such as cell proliferation. This process, primarily linked to the flow of current, supports cell growth and plays a significant role in the healing process.

There is a lack in quantitative knowledge and information in the published studies about the benefits of TEcar therapy on the improvement of hand function after long flexor tendon repair . So, this study is designed to outline the therapeutic impact of TEcar therapy on pain and ROM after hand flexor tendon repair.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Basma Rajai Amer Amer, B.Sc; Phone Number: +20 101 919 0709; Email: Basmarajai3@gmail.com
• Study Contact Backup: Name: Ahmed Mahmoud Ali Gabr Zarraa, PhD

Study Locations

• Egypt
  • Ismailia, Egypt
    • Suez Canal University Hospital
    • Contact: Basma Rajai Amer Amer, B.Sc; Phone Number: +20 101 919 0709; Email: Basmarajai3@gmail.com
    • Contact: Ahmed Mahmoud Ali Gabr Zarraa, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Ages of patients will be ranged from 20 to 35 years.
• All patients underwent flexor tendon primary direct repair
• All patients will be referred by a surgeon before starting the study procedure.

Exclusion Criteria:

• Patient with digital nerve repairs.
• Patients with associated vascular injuries requiring arterial repair.
• Patients with associated crush injuries and soft tissue loss.
• Patients with associated bone fractures.
• Patients with associated extensor tendon injuries .
• Patients with preexisting problems limiting joint motion.
• Patients with diminished cognitive capacity.
• Patients with history of previously failed repair.
• Patients with allergic reactions to certain substances in the conductive cream
• Patients with sensation impairment .

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Transfer Energy Capacitive and Resistive (TECAR) therapy + Early mobilization protocol; It will receive Transfer Energy Capacitive and Resistive (TECAR) therapy in addition to early mobilization protocol for a month.	Device: Transfer Energy Capacitive and Resistive (TECAR) therapy; Before each session, cables will be checked, the therapist will explain the procedure, the patient will be positioned comfortably, and conductive cream will be applied. The active electrode will be moved in circular motions over the injured tendon while the inactive electrode will be placed under the forearm. Intensity will be set to a comfortable, moderate level based on patient sensation. Radio-frequency (RF) energy will be delivered via capacitive mode for 2 minutes per digit, then resistive mode for 4 minutes per digit (total 6 minutes per digit). Treatment will include 8 sessions, twice weekly.; Other: Early mobilization protocol; The dorsal splint/cast will position the wrist at neutral or 15-30° extension with metacarpophalangeal (MCP) joints at 70-90° flexion, featuring low edges for exercise without removal. It will be worn full-time for the first 3 weeks post-surgery, then based on environmental safety (only during sleep and outside home if safe) for weeks 4-6. Patients will begin outpatient physical therapy from week 1 with active mobilization and home exercises every 2 hours. Dressings will be changed every other day. During weeks 1-2, passive/active flexion/extension will follow the Duran protocol (25-50% range of motion) with splint worn during therapy. Weeks 3-4 will progress to 75-100% range of motion, with splint removal at week 4 for active tenodesis exercises. Weeks 5-6 will add tendon gliding, blocking exercises, and light activities while avoiding strenuous lifting or gripping. This progressive protocol will ensure safe healing while gradually restoring function.
Active Comparator: Early mobilization protocol; It will receive their early mobilization protocol only for a month.	Other: Early mobilization protocol; The dorsal splint/cast will position the wrist at neutral or 15-30° extension with metacarpophalangeal (MCP) joints at 70-90° flexion, featuring low edges for exercise without removal. It will be worn full-time for the first 3 weeks post-surgery, then based on environmental safety (only during sleep and outside home if safe) for weeks 4-6. Patients will begin outpatient physical therapy from week 1 with active mobilization and home exercises every 2 hours. Dressings will be changed every other day. During weeks 1-2, passive/active flexion/extension will follow the Duran protocol (25-50% range of motion) with splint worn during therapy. Weeks 3-4 will progress to 75-100% range of motion, with splint removal at week 4 for active tenodesis exercises. Weeks 5-6 will add tendon gliding, blocking exercises, and light activities while avoiding strenuous lifting or gripping. This progressive protocol will ensure safe healing while gradually restoring function.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Active range of motion (ROM) of the proximal interphalangeal (PIP) joint	Active ROM of the PIP joint will be assessed, at the 2nd, 4th, and 6th postoperative weeks using a finger goniometer, with the patient sitting, forearm mid-position and supported on a plinth. The therapist will stabilize the metacarpophalangeal (MCP) joint in 90° flexion at the injured phalanx. The goniometer's axis will be placed over the upper surface of the PIP joint, with the stationary arm aligned to the proximal phalanx's longitudinal axis and the movable arm aligned to the middle phalanx's longitudinal axis. The patient will be instructed to actively flex and then extend the PIP joint through its full range (normally 0°-100°), and the measured ROM will be recorded.	one month
Active range of motion (ROM) of the distal interphalangeal (DIP) joint	Active ROM of the DIP joint will be assessed with the patient seated, forearm in mid-position and supported on the plinth. From a neutral wrist position, the therapist will stabilize the metacarpophalangeal (MCP) joint in 90° flexion and the middle phalanx in extension. The goniometer axis will be placed over the upper surface of the DIP joint, with the stationary arm aligned to the middle phalanx's longitudinal axis and the movable arm aligned to the distal phalanx. The patient will actively flex and extend the DIP joint through its full range (0°-90°), and the ROM will be recorded.	one month

Collaborators and Investigators

• Sponsor: Cairo University
• Investigators: Study Chair: Hsham Mahran, PhD, Professor, Cairo university; Study Director: Ahmed Mahmoud Ali Gabr Zarraa, PhD, Lecturer, Cairo university; Study Director: Amr Abdallah Gomaa, PhD, Assistant Professor, Suez Canal University

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): February 1, 2026
• Study Completion (Estimated): February 15, 2026

Study Registration Dates

• First Submitted: November 20, 2025
• First Submitted That Met QC Criteria: November 20, 2025
• First Posted (Actual): December 1, 2025

Study Record Updates

• Last Update Posted (Actual): December 1, 2025
• Last Update Submitted That Met QC Criteria: November 20, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Therapeutics
• Other Study ID Numbers: P.T.REC/012/006005

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No